Sugi Predict

Sugi Predict / Compounds / SCHEMBL520065

SCHEMBL520065

SCHEMBL520065

O=C1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.59
▸ RAB9A P51151 3/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ GAA P10253 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ CYP2C19 P33261 1/20 0.48
▸ CASP1 P29466 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ CTRB1 P17538 1/20 0.46
▸ P2RX4 Q99571 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ TMEM97 Q5BJF2 2/20 0.45
▸ SIGMAR1 Q99720 2/20 0.45
▸ PARP1 P09874 1/20 0.45
▸ P2RX1 P51575 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520364 0.95 NPC1 (0.58) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL31350203 0.94 NPC1 (0.57) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL2539997 0.91 NPC1 (0.67) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL7326923 0.87 NPC1 (0.50) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL7429283 0.85 NPC1 (0.59) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL19491933 0.83 MEN1 (0.64) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL8327710 0.82 P2RX4 (0.45) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL29235094 0.82 NPC1 (0.61) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL15010933 0.82 NPC1 (0.53) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL17675590 0.82 RAB9A (0.64) NPC1RAB9AL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3712262-B1 TRANSAMINASE MUTANT AND APPLICATION THEREOF ASYMCHEM LIFE SCIENCE TIANJIN CO LTD (CN) 2025-05-21 — — EP disclosed
US-11952575-B2 Transaminase mutant and use thereof ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (CN) 2024-04-09 — — US disclosed
US-20230098847-A1 QUATERNARY HETEROATOM CONTAINING COMPOUNDS CALIFORNIA INSTITUTE OF TECHNOLOGY 2023-03-30 — — US disclosed
US-11390585-B2 Quaternary heteroatom containing compounds CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-07-19 — — US disclosed
CN-114667167-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2022-06-24 — — CN disclosed
CN-112094830-B Transaminase mutants and uses thereof 凯莱英生命科学技术(天津)有限公司 2022-06-24 — — CN disclosed
EP-3974523-A1 TRANSAMINASE MUTANT AND USE THEREOF Asymchem Life Science (Tianjin) Co., Ltd (CN) 2022-03-30 — — EP disclosed
WO-2021127986-A1 NICOTINE PREPARATION METHOD 深圳雾芯科技有限公司 2021-07-01 — — WO disclosed
US-20210155592-A1 QUATERNARY HETEROATOM CONTAINING COMPOUNDS CALIFORNIA INSTITUTE OF TECHNOLOGY 2021-05-27 — — US disclosed
EP-3808177-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS Arbutus Biopharma Corporation (CA) 2021-04-21 — — EP disclosed
CN-100396680-C Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2008-06-25 — — CN disclosed
US-20070207968-A1 Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) 2007-09-06 — — US disclosed
WO-2007060526-A1 SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS PFIZER PRODUCTS INC. (US) 2007-05-31 — — WO disclosed
EP-1768665-A1 PEPTIDOMIMETIC INHIBITORS OF RETROVIRAL PROTEASES AND THEIR USE AS ANTIVIRALS Universita'Degli Studi di Trieste (IT) 2007-04-04 — — EP disclosed
WO-2005123067-A1 PEPTIDOMIMETIC INHIBITORS OF RETROVIRAL PROTEASES AND THEIR USE AS ANTIVIRALS UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) 2005-12-29 — — WO disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 — — CN disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 — — CN disclosed
US-5880284-A HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS DR. KARL THOMAE GMBH (DE) 1999-03-09 — — US disclosed
US-5681841-A PREVENTION CELL AGGREGATION KARL THOMAE GMBH (DE) 1997-10-28 — — US disclosed
EP-0587134-A2 Cyclic urea derivatives, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1994-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155592-A1 QUATERNARY HETEROATOM CONTAINING COMPOUNDS SDHA, NQO1, SDHB NPC1 1902/4885RAB9A 904/4885L3MBTL1 4385/4885
US-11390585-B2 Quaternary heteroatom containing compounds SDHA, NQO1, SDHB NPC1 1902/4885RAB9A 904/4885L3MBTL1 4385/4885
US-20070207968-A1 Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals PREP, PEPD, DNPEP NPC1 3657/4885RAB9A 3066/4885L3MBTL1 452/4885
US-20230098847-A1 QUATERNARY HETEROATOM CONTAINING COMPOUNDS SDHA, NQO1, SDHB NPC1 1902/4885RAB9A 904/4885L3MBTL1 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.